Gilead Sciences
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.41 | 24 |
| immunology | ×1.04 | 3 |
| gastroenterology | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.50 | 9 |
| phase 3 | ×1.50 | 7 |
| phase 1 | ×0.98 | 6 |
| phase 2 | ×1.50 | 6 |
| preclinical | ×0.98 | 6 |
Strategy profile
Based on 15 disclosed transactions, Gilead Sciences concentrates its licensing activity in Oncology, Immunology, and InfectiousDisease. Gilead Sciences pays a 1.42x premium over market median, with the strongest premiums in Gastroenterology (1.50x). Their most common deal structure is Acquisition, with an average disclosed value of $2.2B. Most recent activity: 2026.
Premium by therapeutic area
How Gilead Sciences pays relative to peer medians in each TA
Pipeline coverage & gaps
Gilead Sciences has disclosed activity in 3 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 5 | $3.6B | $4.4B |
| LicensePrimary | 5 | $122M | $1.2B |
| Option | 3 | $61M | $499M |
| Collaboration | 2 | $898M | $1.9B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | gamgertamig (OM336) | Lakefront Biotherapeutics | autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) | phase_1 | $1.7B | $2.2B |
| 2026 | TUB-040 | Tubulis | platinum-resistant ovarian cancer, non-small cell lung cancer | phase_2 | $3.1B | $5.0B |
| 2026 | Tubulis ADC platform/pipeline | Tubulis GmbH | oncology | unknown | — | $5.0B |
| 2026 | OM336 (gamgertamig) | Ouro Medicines | autoimmune_diseases | phase_1 | $1.7B | $2.2B |
| 2026 | OM336 (gamgertamig, BCMAxCD3 TCE) | Ouro Medicines | autoimmune disease | preclinical | $1.7B | $2.2B |
| 2026 | anito-cel | Arcellx | multiple myeloma | phase_3 | $7.8B | $7.8B |
| 2026 | GH31 | Genhouse Bio | MTAP-deleted solid tumors | phase_1 | $80M | $1.5B |
| 2025 | ABI-5366 + ABI-1179 (HSV) | Assembly Biosciences | Recurrent genital herpes (HSV-2) | phase_1 | $35M | $365M |
| 2025 | — | Pregene | hematological | unknown | $120M | $1.6B |
| 2025 | CDK2 molecular glue degrader | Kymera Therapeutics | breast cancer and other solid tumors | preclinical | $40M | $750M |
| 2025 | oral STAT6 inhibitor program | LEO Pharma | inflammatory diseases | preclinical | $250M | $1.7B |
| 2024 | sle_lupus | Kyverna Therapeutics | sle_lupus | phase_1 | $200M | $1.8B |
| 2024 | HBV portfolio | Assembly Biosciences | Chronic hepatitis B | phase_2 | $100M | $100M |
| 2024 | efarindodekin alfa | Xilio Therapeutics | advanced solid tumors | phase_1 | $44M | $648M |
| 2024 | XTX301 | Xilio Therapeutics | solid tumors | phase_1 | $44M | $723M |
How this is computed
For each Gilead Sciences deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 34 disclosed deal premiums vs. peer medians. Raw premium 1.421, clamped to [0.7, 1.5].